Long-Term Efficacy of Serenoa repens Treatment in Patients with Mild and Moderate Symptomatic Benign Prostatic HyperplasiaSinescu I. · Geavlete P. · Multescu R. · Gangu C. · Miclea F. · Coman I. · Ioiart I. · Ambert V. · Constantin T. · Petrut B. · Feciche B.
aDepartment of Urological Surgery, Dialysis and Kidney Transplantation, Fundeni Clinical Institute, bDepartment of Urology, ‘Saint John’ Clinical Emergency Hospital, and c‘Prof. Dr.Th. Burghele’ Urology Clinical Hospital, Bucharest; dDepartment of Urology, Clinical Emergency Hospital, Timisoara; e‘Vasile Goldis’ University of Medicine, Department of Urology, Arad; fUniversity City Hospital and gOncological Institute ‘Ion Chiricuta’, Cluj, Romania
Introduction: The study aimed to evaluate the long-term efficacy of treatment with extract of Serenoa repens (Prostamol Uno) in patients with lower urinary tract symptoms (LUTS) induced by benign prostatic hyperplasia (BPH). Patients and Methods: We studied 120 patients with mild or moderate LUTS induced by BPH, maximal urinary flow (Qmax) <15 ml with a voided volume ≧150 ml, prostate-specific antigen <4 ng/ml, and residual urinary volume <150 ml, treated daily for 24 months with one capsule of 320 mg ethanolic extract of Serenoa repens. Results: Statistically significant improvements in the International Prostate Symptom Score (5.5 points), quality of life (QoL; 1.8 points), Qmax (5.6 ml/s), International Index of Erectile Function (IIEF; 6.4 points) and reduction in residual urinary volume were observed during the study period. The mean prostate volume at 24 months was 36 ml, compared to 39.8 ml at baseline. Conclusions: Long-term treatment with 320 mg ethanolic extract of Serenoa repens proved to be efficient in reducing urinary obstruction, improving symptomatology and QoL of BPH patients. It also had a positive effect on sexual function, demonstrated by the statistically significant increase in the IIEF.